↑ 薬物リストへ　← 戻る

Gm-csf inhalation therapy    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
229肺胞蛋白症（自己免疫性又は先天性）1

229. 肺胞蛋白症（自己免疫性又は先天性）　［臨床試験数：35，薬物数：30（DrugBank：8），標的遺伝子数：3，標的パスウェイ数：12］
Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 35 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-JMA-IIA00205
20/07/201607/01/2015Pulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in JapanPulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in Japan autoimmune pulmonary alveolar proteinosisIntervention type:DRUG. Intervention1:GM-CSF inhalation therapy, Dose form:INJECTION, Route of administration:INHALATIONAL, intended dose regimen:125mcg BID inhalation for 7days and 7days without inhalation, 12 cycles. Control intervention1:placebo controlled, Dose form:INJECTION, Route of administration:INHALATIONAL, Intended dose regimen:placebo BID inhalation for 7days and 7days without inhalation, 12 cycles.Koh NakataPartner TherapeuticsCompleted>=16 YEARS<=80 YEARSBOTH80Japan